Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · IEX Real-Time Price · USD
4.740
-0.030 (-0.63%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Prelude Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Selling, General & Admin
28.8830.6526.9610.593.832.35
Research & Development
103.3992.8986.7848.1824.2812.62
Operating Expenses
132.28123.54113.7458.7628.1114.98
Operating Income
-132.28-123.54-113.74-58.76-28.11-14.98
Other Expense / Income
-10.45-8.1-2.04-1.83-0.54-0.3
Pretax Income
-121.83-115.44-111.69-56.93-27.57-14.68
Net Income
-121.83-115.44-111.69-56.93-27.57-14.68
Shares Outstanding (Basic)
6047461222
Shares Outstanding (Diluted)
6047461222
Shares Change
27.41%2.87%269.03%647.86%2.83%-
EPS (Basic)
-2.02-2.44-2.43-4.56-16.52-9.05
EPS (Diluted)
-2.02-2.44-2.43-4.56-16.52-9.05
Free Cash Flow
-110.58-86.75-85.85-46.8-26.45-13.48
Free Cash Flow Per Share
-1.83-1.83-1.86-3.75-15.85-8.31
EBITDA
-118.73-112.4-109.45-56.39-27.19-14.53
Depreciation & Amortization
3.113.042.240.540.380.15
EBIT
-121.83-115.44-111.69-56.93-27.57-14.68
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).